Combining EZH2 inhibitors with other therapies for solid tumors: more choices for better effects.
Sign Up to like & getrecommendations! Published in 2023 at "Epigenomics"
DOI: 10.2217/epi-2022-0320
Abstract: EZH2 is an epigenetic regulator that methylates lysine 27 on histone H3 (H3K27) and is closely related to the development and metastasis of tumors. It often shows gain-of-function mutations in hematological tumors, while it is… read more here.
Keywords: therapies solid; combining ezh2; tumors choices; inhibitors therapies ... See more keywords